Get API key
Reporting owner · Q3 2026 · CIK 1930214

Vivo Opportunity Fund Holdings, L.P.: insider trades.

Vivo Opportunity Fund Holdings, L.P. reported 12 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 12 open-market purchases ($42K) and 0 sales, across 1 company.

Transactions
12
Purchases (P)
12
Sales (S)
0
Companies
1
Name as filed
Vivo Opportunity Fund Holdings, L.P.

Companies

CompanyRelationshipTransactions
InMed Pharmaceuticals Inc. (INM)TenPercentOwner12

Transactions

12 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-07-16InMed Pharmaceuticals Inc.P2$1.5575,019Form 4
2026-07-16InMed Pharmaceuticals Inc.P19$1.55743,057Form 4
2026-07-15InMed Pharmaceuticals Inc.P1,389$1.5575,017Form 4
2026-07-15InMed Pharmaceuticals Inc.P13,761$1.55743,038Form 4
2026-07-14InMed Pharmaceuticals Inc.P493$1.5573,628Form 4
2026-07-14InMed Pharmaceuticals Inc.P4,882$1.55729,277Form 4
2026-07-02InMed Pharmaceuticals Inc.P147$1.5573,135Form 4
2026-07-02InMed Pharmaceuticals Inc.P1,460$1.55724,395Form 4
2026-07-01InMed Pharmaceuticals Inc.P398$1.5572,988Form 4
2026-07-01InMed Pharmaceuticals Inc.P3,946$1.55722,935Form 4
2026-06-30InMed Pharmaceuticals Inc.P545$1.54718,989Form 4
2026-06-30InMed Pharmaceuticals Inc.P55$1.5472,590Form 4

Questions

What stock did Vivo Opportunity Fund Holdings, L.P. buy or sell?

Vivo Opportunity Fund Holdings, L.P. reported 12 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 12 open-market purchases ($42K) and 0 sales, across 1 company.

Is Vivo Opportunity Fund Holdings, L.P. the same person as other filers with this name?

This page covers SEC CIK 1930214 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/vivo-opportunity-fund-holdings-l-p-1930214.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.